Headline
The latest stories from AHA Today.
The Centers for Medicare & Medicaid Services’ Innovation Center released a strategic plan to guide its health care payment and delivery models and priorities over the next decade.
Workplace violence spurred AHA’s Hospitals Against Violence advisory group to create a framework to support hospitals’, health systems’ and security leaders’ efforts to safeguard staff and patients, writes Mary Beth Kingston, R.N., chair of the group, chief nurse officer at Advocate Aurora Health…
Sens. Roger Marshall, R-Kan., Kyrsten Sinema, D-Ariz., and John Thune, R-S.D., introduced a Senate companion to AHA-supported legislation (H.R. 3173/S. 3018) that would establish requirements for the use of prior authorization under Medicare Advantage plans.
A mix-and-match vaccine regimen is permissible for international travelers entering the U.S., according to updated Centers for Disease Control and Prevention guidance.
Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969 hospitalized adults with COVID-19 pneumonia in the United States, Japan, Mexico, Singapore and South Korea, the National Institutes of Health…
The Health Resources and Services Administration Oct. 21 will host the last in a series of webinar sessions on how to apply for a portion of $25.5 billion in COVID-19 relief funds.
Two doses of the Pfizer vaccine are 93% effective at preventing COVID-19 hospitalization among children aged 12 to 18, according to a study at 19 pediatric hospitals released by the Centers for Disease Control and Prevention.
The AHA urged the Centers for Medicare & Medicaid Services to conduct the necessary oversight and enforcement of the No Surprises Act to ensure patients benefit from these new protections and to prevent widespread, negative consequences of any misapplication of the policy.
Nearly three-fourths of the 2.4 million U.S. adults who reported using buprenorphine in 2019 did not misuse the medication in the past 12 months, according to a National Institutes of Health study released in JAMA Network Open.
The Food and Drug Administration approved the first interchangeable biosimilar product for Humira, a monoclonal antibody used to treat certain inflammatory diseases.